At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,036 enrolled
Drug / intervention
Silodosindrug
Likely dose
Silodosin 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness and Safety of Silodosin in the Treatment of LUTS in Patients With Benign Prostatic Hyperplasia: a European Phase IV Clinical Study. The Silodosin in Real-life Evaluation Study
In Brief
A Phase 4 clinical trial evaluating Silodosin for Benign Prostatic Hyperplasia. Completed, enrolled 1,036 participants across 1 site.
Detailed Summary
The purpose of this study is to confirm in a larger population in Europe the effectiveness and safety observed with silodosin in previous clinical trials.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hyperplasia
CountriesItaly
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
First PostedDec 2012
Primary CompletionMar 2013
Study CompletionAug 2013
TodayJul 2026
First PostedDec 31, 2012
Enrollment StartMay 1, 2011
Primary CompletionMar 1, 2013
Study CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.5 years ago
Interventions
Silodosindrug
8 mg daily for 24 weeks